ALL-REZ Registry

Relapse of an acute lymphoblastic leukeamia

Registry

• Possibly the complete registration of all children and adolescents with a first or further relapse of ALL, who are not participating in an IntReALL-trial
• Continuation of the etablished refererence diagnostics and biobanking
• Guarantee of a longtime follow-up of the patients also after closing of the primary trial

By recording all children and adolescents with an ALL recurrence as completely as possible in a registry, epidemiological statements can be made about the incidence, course and prognosis of children with ALL recurrence. This group contributes to the mortality of children with malignant diseases like no other. Patients can be systematically followed up.
Late effects can be recorded and correlated with previous therapies and clinical factors. Corresponding risks can be taken into account in future treatment strategies. As a competence center for relapsed/refractory ALL, the study center can advise participating centers on specific questions regarding individual treatment strategies as well as radiation and transplant indications. Patients with relapsed and/or refractory ALL can be advised on treatment in an open AMG trial and assigned accordingly.

The treatment instructions attached to this protocol in this specific form and combination do not represent recommendations for a generally recognized treatment, but are rather guidelines for treatment.
The risk groups S1 to S4 are classified according to the definition of the ALL-REZ BFM 2002 study. The only change to this classification is the categorization of very early isolated extramedullary recurrences in the S4 group. Due to the good results of the ALL-REZ BFM 2002 study, treatment according to the ALL-REZ BFM 2002 protocol is still recommended for children and adolescents with 1st ALL recurrence until the start of the new international ALL recurrence study. Consolidation is carried out with protocol II-Ida. In the event of a subsequent relapse, consultation with the study center is recommended.

• Diagnosis of a ALL-Relapse (B-precursor or T, isolated or combined medullary or eytramedullary)
• Registry:
• Informed consent
• Tumorbanking:
• Informed consent tumorbanking and concomitant research